Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Lilly

Alzheimer’s drug rejected for widespread use by NHS spending watchdog

Donanemab is a so-called disease-modifying treatment.

Evening Standard

Wes Streeting says weight-loss jabs for unemployed not 'dystopian'

THE UK’s Health Secretary has denied his plans to give weight-loss jabs to unemployed people would result in a “dystopian future”.

The National (Scotland)

Pumping the unemployed with weight-loss drugs echoes Victorian attitudes to the poor

Shifting blame to the victims of economic policy is an old trick by politicians. Now they’re using obesity to tackle joblessness

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Experts weigh in on Labour plan to offer weight loss jabs to unemployed

LABOUR plans to give obese and unemployed people weight-loss jabs as part of a drive to get them back into work and reduce pressure on the NHS…

The National (Scotland)

Unemployed to be given weight-loss jags as part of UK plan to 'get them back to work'

THE Health Secretary has said unemployed people will be given weight-loss injections as part of a UK Government drive to “get them back to…

The National (Scotland)

Meet the 9 CFOs on Fortune’s 2024 Most Powerful Women list

The list of 100 executives spans the globe.

Fortune

Is Eli Lilly Stock Still a Buy Near All-Time Highs?

With a robust performance, strategic expansions, and strong analyst endorsements, Eli Lilly appears poised for continued growth, making it a compelling investment opportunity.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Snag This Biotech Stock Before November, Here's Why

With Viking Therapeutics making a splash in the weight-loss drug arena, one analyst is encouraging investors to snap up the stock before a November catalyst.

Barchart

Eli Lilly's new CFO is a 23-year company veteran—showing how pharma firms rely on a 'deep bench of qualified talent'

Lucas Montarce's career path at the company is similar to that of his predecessor, Anat Ashkenazi.

Fortune

Eli Lilly Names New CFO Amid Weight-loss Drug Expansion Plan

U.S. pharmaceutical giant Eli Lilly named a new chief financial officer on Monday during a critical time for the company's exploding weight-loss drug market.

International Business Times

How Is Eli Lilly’s Stock Performance Compared to Other Drug Manufacturer Stocks?

Eli Lilly has recently outperformed the general drug manufacturers industry, and analysts are highly optimistic about the stock’s prospects.

Barchart

Former Maryland Resident Sentenced For Congressional Office Harassment

Former Maryland resident sentenced to prison for making threatening calls to congressional offices, highlighting the seriousness of threats against elected...

Top News

Man sentenced to over 1 year in prison for thousands of harassing calls to congressional offices

A former Maryland resident has been sentenced to more than one year behind bars for making thousands of threatening and harassing telephone calls to dozens of congressional offices across the country

The Independent UK

3 Mega-Cap Stocks Not Named Nvidia Up More than 40% in 2024

Shares of mega-cap stocks such as Walmart, Meta Platforms, and Eli Lilly have surged over 40% in 2024, outpacing the broader markets by a wide margin.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

International Business Times

Eli Lilly Launches Discount Anti-Obesity Drug

The company claims the Zepbound doses cost 50% less than competing drugs

Barchart

Up 58% YTD, is Eli Lilly Stock Still a Buy?

The pharmaceutical giant has already delivered massive gains this year, but Wall Street analysts have only gotten more bullish on the maker of Mounjaro and Zepbound.

Barchart

1 Billionaire-Backed Penny Stock With 421% Upside

Down 96% from all-time highs, AbCellera Biologics is a biotech stock with massive upside potential, given consensus price target estimates.

Fortune

How Eli Lilly went from pharmaceutical slowpoke to $791 billion juggernaut

Tirzepatide, a drug for diabetes and obesity, has sent the 148-year-old pharma giant on a wild ride. It’s now the ninth most valuable company in the world.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Should You Buy These Stocks Before They Join The $1 Trillion Market Cap Club?

Their strong fundamentals, brand strength, and drive to succeed could propel their stock higher.

International Business Times UK

Jim Cramer Names Six Companies That May Enter the Trillion-Dollar Stock Club

In a recent episode of CNBC's Mad Money show, Jim Cramer named companies like Eli Lilly, Tesla, JPMorgan, and Walmart that could reach a $1 trillion market valuation.

TV Tech

NBCU to Offer First-Ever Commercial-Free Hour During Live Coverage of the Olympics Opening Ceremony

The commercial-free hour, which begins at 1:30 p.m. ET on July 26, is sponsored by Coke, Delta, Eli Lilly, Toyota, Visa, and Xfinity

The Guardian - US

Ozempic knockoffs flood US market thanks to ‘blind spot’ in FDA rules

Pharmacy alliance president counters that ‘it’s an intentional policy’ so patients don’t go without medication

The Independent UK

Weight-loss war heats up as Wegovy rival found to lead to faster and greater results

Shares in Novo Nordisk were down 1.1% after the study

The Independent UK

A weight loss miracle! New shot does better than Ozempic and Wegovy during trials

Tirzepatide, which is sold under the brand names Mounjaro and Zepbound – which treat diabetes and weight loss, respectively – leads to more weight loss than semaglutide, new research has shown

Medical Daily

What Is Kisunla? Know All About New FDA-Approved Drug For Alzheimer's Disease

Kisunla manufactured by Eli Lilly could significantly slow cognitive decline in people with early symptomatic Alzheimer's disease, according to results of the company's clinical trials.

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations